Robinhood and Ligand to Raise $2.5B via Convertible Notes for Growth and Buybacks

Key Facts

In a move reflecting corporate efforts to capitalize on favorable market conditions to bolster liquidity, Robinhood announced its intention to offer $2.0 billion of convertible senior notes due 2029. Simultaneously, Ligand Pharmaceuticals plans to offer $550 million of convertible notes due 2031. Both companies intend to use a portion of the proceeds for share repurchases, a strategy designed to offset potential dilution for existing shareholders that often accompanies convertible debt issuances.

This trend emerges as fintech and healthcare firms increasingly utilize convertible notes as a lower-cost alternative to traditional debt; global convertible issuance has seen significant growth in the first half of 2026 per market data. Comparing this to peers, companies like Coinbase have previously executed similar capital raises to fund strategic growth, highlighting a sector-wide shift toward enhancing financial flexibility while managing equity dilution risks.

Investors should monitor current price levels, with HOOD closing at $108.15 and LGND at $274.88 (close June 18, 2026). Looking ahead, the market awaits upcoming U.S. retail sales and housing data later this week, which could influence risk appetite across the technology and biotech sectors and impact the trading performance of these newly issued instruments.